Nature Communications (May 2018)
In vivo reprogramming drives Kras-induced cancer development
- Hirofumi Shibata,
- Shingo Komura,
- Yosuke Yamada,
- Nao Sankoda,
- Akito Tanaka,
- Tomoyo Ukai,
- Mio Kabata,
- Satoko Sakurai,
- Bunya Kuze,
- Knut Woltjen,
- Hironori Haga,
- Yatsuji Ito,
- Yoshiya Kawaguchi,
- Takuya Yamamoto,
- Yasuhiro Yamada
Affiliations
- Hirofumi Shibata
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Shingo Komura
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yosuke Yamada
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Nao Sankoda
- Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Akito Tanaka
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Tomoyo Ukai
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Mio Kabata
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Satoko Sakurai
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Bunya Kuze
- Department of Otolaryngology, Gifu University Graduate School of Medicine
- Knut Woltjen
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital
- Yatsuji Ito
- Department of Otolaryngology, Gifu University Graduate School of Medicine
- Yoshiya Kawaguchi
- Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Takuya Yamamoto
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yasuhiro Yamada
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University
- DOI
- https://doi.org/10.1038/s41467-018-04449-5
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Cellular reprogramming and cancer development share properties. Here, the authors examine the impact of in vivo reprogramming on Kras-induced cancer and show reprogramming-mediated repression of somatic cell enhancers in conjunction with Kras mutation results in rapid PDAC development.
